CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 209 enrolled
Drug / intervention
Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01629823
NCT01629823N/ACompleted
CompareCT.gov

Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma

American Lung Association Asthma Clinical Research Centers·interventional·Posted Jun 28, 2012·Updated May 15, 2017

In Brief

A clinical study evaluating Continuous Positive Airway Pressure device (Resmed, Swift, Mirage) for Asthma. Completed, enrolled 209 participants across 18 sites.

Detailed Summary

The CPAP trial is a 3-arm parallel design randomized sham-controlled trial. Participants are randomly assigned in equal allocation to one of three treatments: CPAP 10 cm water (H₂O) (high) vs. CPAP 5 cm H₂O (medium) vs. CPAP Sham (less than 1 cm H₂O, Low). The treatment period is 12 weeks with airways reactivity assessed at baseline, 6 and 12 weeks of treatment and after a 2 week washout.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 28, 2012
Enrollment StartJul 1, 2012
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.0 years ago

Interventions

Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)device

Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.